Nadine McGrath

The 2024 Bioshares Biotech Summit is being held in Fremantle from July 12-13 Day two’s focus is on new companies, diagnostics and those following a new direction Trends in healthcare and biotech sector a focus as investor sentiment improves Although Western Australia is usually known for its resources, biotech and life sciences is stealing the spotlight this week with the 18th annual Bioshares Biotech Summit in Fremantle from July 12-13. Stockhead columnist Tim Boreham has sugg…

Australia could bolster onshore health and medical products manufacturing to commercialise world-leading research and develop its skill base.

In this episode of the Vital Signs Podcast, host Nadine chats to CFO at Aroa Biosurgery (ASX:ARX), James Agnew.

With sleep considered vital for health and wellbeing these three ASX stocks are focused on ensuring we all get a good night rest.

Australia is focusing on digital innovation for a more connected, efficient healthcare system with government and industry initiatives.

Australia has a reputation as an attractive clinical trials destination generating $1.6bn for the economy in 2022, according to MTPConnect.

Several ASX companies are conducting clinical trials, and this has become a valuable sector and an asset to the Australian economy.

Technology is disrupting traditional medical practices, with locally listed companies at forefront of innovation including Optiscan (ASX:OIL).

Online investment platform Stockspot has compiled a list of 13 ETFs which have generated returns above 25% in the past year.

Scott Power had his eyes on Sigma Healthcare this week, which soared after the ACCC approves its merger with Chemist Warehouse.